Blocking ATM activation aims to sensitize cancer cells to chemotherapy, but this approach may result in toxicities to healthy cells that rely on ATM for DNA repair and affect numerous ATM substrates, including tumor suppressors such as Brca1 and p53. This evidence concerns the gene TP53 and cancer.